Prothena Corp Plc(PRTA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.83 | Insider Own | 14.46% | Shs Outstand | 51.7M | Perf Week | 13.33% |
| Market Cap | 0.47B | Forward P/E | - | EPS next Y | -962.65% | Insider Trans | 22.92% | Shs Float | 43.9M | Perf Month | 3.64% |
| Enterprise Value | 0.19B | PEG | - | EPS next Q | -0.23 | Inst Own | 92.68% | Short Float | 18.08% | Perf Quarter | 8.2% |
| Income | -0.04B | P/S | 8.57 | EPS this Y | 102.62% | Inst Trans | -1.47% | Short Ratio | 16.61 | Perf Half Y | -16.28% |
| Sales | 0.05B | P/B | 1.64 | EPS next 5Y | 60.56% | ROA | -12.54% | Short Interest | 7.94M | Perf YTD | -4.71% |
| Book/sh | 5.54 | P/C | 1.62 | EPS past 3/5Y | -22.46% -10.24% | ROE | -14.39% | 52W High | -22.88% ($11.80) | Perf Year | -13.66% |
| Cash/sh | 5.61 | P/FCF | - | Sales past 3/5Y | -43.57% 62.56% | ROIC | -15.12% | 52W Low | 17.72% ($7.73) | Perf 3Y | -74.55% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 85.31% | Gross Margin | 93.18% | Volatility(W/M) | 4.98% 5.12% | Perf 5Y | -83.91% |
| Dividend TTM | - | EV/Sales | 3.41 | Sales Y/Y TTM | 427.32% | Oper. Margin | -109.79% | ATR (14) | 0.41 | Perf 10Y | -82.35% |
| Dividend Ex-Date | - | Quick Ratio | 25.05 | EPS Q/Q | 84.75% | Profit Margin | -80.67% | RSI (14) | 59.87 | Recom | 2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 25.05 | Sales Q/Q | -77.15% | SMA20 | 7.76% ($8.44) | Beta | -0.2 | Target Price | $19.6 |
| Payout | - | Debt/Eq | 0.02 | Earnings | 2026/8/6 | SMA50 | 3.61% ($8.78) | Rel Volume | 1.57 | Prev Close | $8.81 |
| Employees | 67 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | 7.69% 139.51% | SMA200 | -1.53% ($9.24) | Avg Volume(3M) | 0.48M | Price | $9.1 |
| IPO | 2012/12/21 | Option/Short | Yes/Yes | Trades | 6914 | Volume | 752,029 | Change | 3.29% |
🧬 This is a clinical-stage biotech company developing antibody-based therapeutics that target neurodegenerative and protein-aggregation diseases such as Alzheimer's, Parkinson's, and amyloidosis. The company is headquartered in Ireland and operates its R&D activities in the United States, expanding its pipeline through partnerships with global pharmaceutical companies such as Roche and Novo Nordisk.
Over the past 1 year, roughly in the middle
23% below its 1-year high.
Traded more than usual. That is 157% of its average volume.
PRTA has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by +102.6% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $857. Peers typically go for $1,237.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -83.9%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 92.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #228 of 594 in the industry
Based on market cap of $467M.
EPRX#225 Eupraxia Pharmaceuticals Inc $480M PER - 
OVID#226 Ovid Therapeutics Inc $478M PER - 
RGNX#227 Regenxbio Inc $478M PER - PRTA#228 Prothena Corp Plc $467M PER - 
PROK#229 ProKidney Corp $460M PER - 
FAQ
What kind of company is PRTA?
PRTA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PRTA?
The market cap of PRTA is approximately $467M, ranking 3,218 within its sector.
What is the 52-week high and low for PRTA?
PRTA has recorded a 52-week high of $11.80 and a low of $7.73.
